Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.36 |
| ▸ | TYK2 | P29597 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2581848 | 0.98 | TERT (0.38) | CHRNB2CHRNA4JAK2JAK3JAK1 | |
| SCHEMBL15507805 | 0.86 | PAICS (0.38) | SIGMAR1TDP1HRH3 | |
| SCHEMBL5198308 | 0.86 | PIM1 (0.41) | JAK2JAK3JAK1TYK2SIGMAR1 | |
| SCHEMBL13541908 | 0.79 | JAK2 (0.37) | JAK2JAK3JAK1TYK2L3MBTL1 | |
| SCHEMBL1703040 | 0.78 | SIGMAR1 (0.41) | JAK2JAK3JAK1TYK2L3MBTL1 | |
| SCHEMBL11946810 | 0.78 | HRH3 (0.42) | JAK2JAK3JAK1TYK2SIGMAR1 | |
| SCHEMBL17793165 | 0.76 | HRH3 (0.41) | JAK2JAK3JAK1TYK2TERT | |
| SCHEMBL1869747 | 0.76 | ALDH1A1 (0.39) | JAK2JAK3JAK1TYK2L3MBTL1 | |
| SCHEMBL1703940 | 0.76 | SIGMAR1 (0.43) | JAK2JAK3JAK1TYK2L3MBTL1 | |
| SCHEMBL10263495 | 0.75 | HRH3 (0.46) | JAK2JAK3JAK1TYK2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101479255-B | C-MET protein kinase inhibitors for the treatment of proliferative disorders | VERTEX PHARMA | 2013-05-01 | — | — | CN | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-1768984-B1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS INC (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7601725-B2 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2004625-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Vertex Pharmaceuticals Incorporated (US) | 2008-12-24 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007111904-A2 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-04 | — | — | WO | disclosed |
| EP-1768984-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | Sunesis Pharmaceuticals, Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006036266-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. (US) | 2006-04-06 | — | — | WO | disclosed |
| US-20060035908-A1 | Thienopyrimidines useful as Aurora kinase inhibitors | SUNESIS PHARMACEUTICALS, INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | CHRNB2 4546/4885CHRNA4 4749/4885JAK2 33/4885 |
| US-20100179123-A1 | THIENOPYRIMIDINES USEFUL AS AURORA KINASE INHIBITORS | AURKA, AURKB, AURKC | CHRNB2 3797/4885CHRNA4 3831/4885JAK2 652/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | CHRNB2 4546/4885CHRNA4 4749/4885JAK2 33/4885 |
| US-20060035908-A1 | Thienopyrimidines useful as Aurora kinase inhibitors | AURKA, AURKB, AURKC | CHRNB2 3891/4885CHRNA4 4066/4885JAK2 563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.